Elatatug

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, elatatug specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells and inhibit tumor cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

**Synonyms:** - Anti-CLDN18.2 Monoclonal Antibody TORL-2-307-MAB - Anti-Claudin18.2 Monoclonal Antibody TORL-2-307-MAB - ELATATUG - TORL-2-307-MAB